{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:03:02Z","timestamp":1788458582532,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":275,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009574","name":"Servicio Murciano de Salud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009574","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Applied"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.nsa.2022.100111","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T06:19:14Z","timestamp":1665209954000},"page":"100111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Comparative effectiveness of long-acting injectable antipsychotics in a large naturalistic cohort across two European centers: Findings from the long-acting injectable antipsychotics collaborative (LAICO) study."],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-7698","authenticated-orcid":false,"given":"Juan Antonio","family":"Garc\u00eda-Carmona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8182-0745","authenticated-orcid":false,"given":"Joshua","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8063-3235","authenticated-orcid":false,"given":"Mar\u00eda Pilar","family":"Campos-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-3419","authenticated-orcid":false,"given":"Katy","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Valdivia-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6303-1547","authenticated-orcid":false,"given":"Sofia","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nsa.2022.100111_bib1","first-page":"445","article-title":"Off-label use of second-generation antipsychotics in borderline personality disoder: a survey of Italian psychiatrists","volume":"33","author":"Aguglia","year":"2019","journal-title":"J.\u00a0Pers. Disord."},{"key":"10.1016\/j.nsa.2022.100111_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2008.01.022","article-title":"Schizophrenia, \u201cjust the facts\u201d: what we know in 2008 part 1: overview","volume":"100","author":"Andon","year":"2008","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.nsa.2022.100111_bib3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/YIC.0000000000000317","volume":"35","author":"Bartoli","year":"2020","journal-title":"Int Clin Psycopharm"},{"key":"10.1016\/j.nsa.2022.100111_bib4","article-title":"STAR netweork depot investigators","volume":"309","author":"Bartoli","year":"2022","journal-title":"Psychatry Res"},{"key":"10.1016\/j.nsa.2022.100111_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/eip.12685","article-title":"Paliperidone palmitate once-every-3-months in adults with early illess schizophrenia","volume":"13","author":"Bell Lynum","year":"2018","journal-title":"Early Int Psychiatry"},{"issue":"5","key":"10.1016\/j.nsa.2022.100111_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40263-021-00812-1","article-title":"Is adjunct aripiprazole effective in treating hyperprolactinemia induced by psychotropic medication? A narrative review","volume":"35","author":"Besag","year":"2021","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.nsa.2022.100111_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.9740\/mhc.2016.09.248","article-title":"Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: a comparison of biweekly versus monthly administered neuroleptics","volume":"6","author":"Carr","year":"2016","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.nsa.2022.100111_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jad.2016.08.023","article-title":"Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: a 1-year retrospective cohort study","volume":"205","author":"Chan","year":"2016","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.nsa.2022.100111_bib9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/03007995.2017.1300144","article-title":"Health care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trials","volume":"33","author":"Chirila","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.nsa.2022.100111_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","article-title":"Pharmacokinetic characteristics of long-acting injectable Antipsychotics for schizophrenia: an overview","volume":"35","author":"Correll","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nsa.2022.100111_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/YCO.0000000000000462","article-title":"Psychotic symptoms in borderline personality disorder: an update","volume":"32","author":"D\u2019Agostino","year":"2019","journal-title":"Curr. Opin. Psychiatr."},{"issue":"6","key":"10.1016\/j.nsa.2022.100111_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179049","article-title":"Treatment continuation of four long-acting antipsychotic medications in The Netherlands and Belgium: a retrospective database study","volume":"12","author":"Decuypere","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.nsa.2022.100111_bib13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/JCP.0000000000001133","article-title":"Efficacy and safety of Paliperidone palmitate treatment in patients with schizophrenia: a real-world multicenter, retrospective, Mirror-image study","volume":"39","author":"Devrimci-Ozguven","year":"2019","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.nsa.2022.100111_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/NDT.S189245","article-title":"Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting","volume":"15","author":"Di Lorenzo","year":"2019","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"9","key":"10.1016\/j.nsa.2022.100111_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.euroneuro.2013.03.001","article-title":"Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials","volume":"23","author":"Dold","year":"2013","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.nsa.2022.100111_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ajp.2019.08.010","article-title":"Prescription of antipsychotic and concomitant medications for adult asian schizophrenia patients: findings of the 2016 research on asian psychotropic prescription patterns (REAP) survey","volume":"45","author":"Dong","year":"2019","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.nsa.2022.100111_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.699748","article-title":"Paliperidone 3-month injection for treatment of schizophrenia: a narrative review","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.nsa.2022.100111_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40261-020-00913-7","article-title":"Long-acting injectable antipsychotics: analysis of prescription patterns and patient characteristics in Mental Health from a Spanish real-world study","volume":"40","author":"Garcia-Carmona","year":"2020","journal-title":"Clin. Drug Invest."},{"issue":"4","key":"10.1016\/j.nsa.2022.100111_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/YIC.0000000000000357","article-title":"Off-label use of second-generation antipsychotics in borderline personality disorder: a comparative real-world study among oral and long-acting injectables in Spain","volume":"36","author":"Garc\u00eda-Carmona","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.nsa.2022.100111_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/YIC.0000000000000339","article-title":"Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain","volume":"36","author":"Garcia-Carmona","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.nsa.2022.100111_bib21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/JCP.0000000000001109","article-title":"Perceptions of psychiatrists toward the use of long-acting injectable Antipsychotics: an online survey study from India","volume":"39","author":"Grover","year":"2019","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"issue":"32","key":"10.1016\/j.nsa.2022.100111_bib22","article-title":"Antipsychotic patterns in outpatients with schizophrenia in China: a cross sectional study","volume":"100","author":"Guo","year":"2021","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.nsa.2022.100111_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2147\/CEOR.S191198","article-title":"Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting","volume":"11","author":"Hodgson","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.nsa.2022.100111_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/NDT.S112063","article-title":"Effects of paliperidone extended release on hostility among Thai patients with schizophrenia","volume":"13","author":"Jariyavilas","year":"2017","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.nsa.2022.100111_bib25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40263-021-00861-6","article-title":"Controversies surrounding the use of long acting injectable antipsychotic medications for the treatment of patients with schizophrenia","volume":"35","author":"Kane","year":"2021","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.nsa.2022.100111_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/schbul\/sbx090","article-title":"Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies","volume":"44","author":"Kishimoto","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.nsa.2022.100111_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatr."},{"issue":"4","key":"10.1016\/j.nsa.2022.100111_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamapsychiatry.2017.4711","article-title":"Real-world effectiveness of pharmacologic treatments for the prevention of re hospitalization in a Finnish nationwide cohort of patients with bipolar disorder","volume":"75","author":"Lahteenvuo","year":"2018","journal-title":"JAMA Psychiatr."},{"issue":"9896","key":"10.1016\/j.nsa.2022.100111_bib29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.nsa.2022.100111_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JCP.0000000000000827","article-title":"Comparison of paliperidone palmitate and risperidone long-acting injection in schizophrenic patients: results from a multicenter retrospective cohort study in France","volume":"38","author":"Limosin","year":"2018","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"issue":"18","key":"10.1016\/j.nsa.2022.100111_bib31","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","volume":"381","author":"Marder","year":"2019","journal-title":"Schizophrenia. N Engl J Med."},{"issue":"3","key":"10.1016\/j.nsa.2022.100111_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/13651501.2020.1767788","article-title":"Maintenance phase treatment of psychotic disorders in outpatients from Serbia - focus on long-term benzodiazepine use","volume":"24","author":"Mari\u0107","year":"2020","journal-title":"Int. J. Psychiatr. Clin. Pract."},{"key":"10.1016\/j.nsa.2022.100111_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2019.08.001","article-title":"A\u00a0controversial gold standard antipsychotic for the 21st century: switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort","volume":"212","author":"Mart\u00ednez-Andr\u00e9s","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.nsa.2022.100111_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20451253211029490","article-title":"Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate","volume":"11","author":"Mason","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"10.1016\/j.nsa.2022.100111_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00002018-200022010-00006","article-title":"Managing antipsychotic-induced acute and chronic akathisia","volume":"22","author":"Miller","year":"2000","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.nsa.2022.100111_bib36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/JCP.0000000000001487","article-title":"Combination therapy of long-acting injectable second-generation antipsychotics and oral antipsychotics: a retrospective chart review and prescribers' attitude survey","volume":"42","author":"Misawa","year":"2022","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.nsa.2022.100111_bib37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/schbul\/sbu128","article-title":"Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study","volume":"41","author":"Nielsen","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.nsa.2022.100111_bib38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.9758\/cpn.2019.17.4.531","article-title":"The impact of paliperidone palmitate on hospitalization in patients with schizophrenia: a retrospective mirror-image study","volume":"17","author":"Oh","year":"2019","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"4","key":"10.1016\/j.nsa.2022.100111_bib39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2019.02.003","article-title":"Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review","volume":"29","author":"Pacchiarotti","year":"2019","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.nsa.2022.100111_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/YIC.0000000000000285","article-title":"Long-term effects of paliperidone palmitate on hospital stay and treatment continuation","volume":"34","author":"Pappa","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.nsa.2022.100111_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045125320924789","article-title":"Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study","volume":"10","author":"Pappa","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"issue":"6","key":"10.1016\/j.nsa.2022.100111_bib56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/YIC.0000000000000095","article-title":"Effectiveness of long-acting paliperidone palmitate in borderline personality disorder","volume":"30","author":"Palomares","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.nsa.2022.100111_bib42","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s10597-021-00780-2","article-title":"Shared and supported decision making in medication in a mental health setting: how far have we come?","volume":"57","author":"Pappa","year":"2021","journal-title":"Community Ment. Health J."},{"issue":"4","key":"10.1016\/j.nsa.2022.100111_bib57","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4088\/JCP.14m09228","article-title":"The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services","volume":"76","author":"Paton","year":"2015","journal-title":"J.\u00a0Clin. Psychiatr."},{"key":"10.1016\/j.nsa.2022.100111_bib43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12888-021-03305-z","volume":"21","author":"Pungor","year":"2021","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.nsa.2022.100111_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jpsychires.2020.06.013","article-title":"Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: a systematic review and meta-analysis","volume":"129","author":"Saucedo Uribe","year":"2020","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.nsa.2022.100111_bib45","doi-asserted-by":"crossref","first-page":"pyw018","DOI":"10.1093\/ijnp\/pyw018","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double bind, noninferiority study","volume":"19","author":"Savitz","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.nsa.2022.100111_bib46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/0269881114541013","article-title":"Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review","volume":"29","author":"Sim","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"issue":"1","key":"10.1016\/j.nsa.2022.100111_bib47","first-page":"81","article-title":"Evaluation of risk factors associated to prescription of benzodiazepines and its patterns in a cohort of patients from Mental Health: a real world study in Spain","volume":"51","author":"Simal-Aguado","year":"2021","journal-title":"Psychopharmacol. Bull."},{"issue":"11","key":"10.1016\/j.nsa.2022.100111_bib48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/2045125318782694","article-title":"Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec","volume":"8","author":"Stip","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"issue":"6","key":"10.1016\/j.nsa.2022.100111_bib49","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","article-title":"Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a Nationwide study with 20-year follow-up","volume":"44","author":"Taipale","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.nsa.2022.100111_bib50","first-page":"681","article-title":"The incidence of akathisia in the treatment of schizophrenia with aripiprazole","volume":"13","author":"Thomas","year":"2015","journal-title":"asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol"},{"key":"10.1016\/j.nsa.2022.100111_bib51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonen","year":"2012","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.nsa.2022.100111_bib52","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J.\u00a0Clin. Epidemiol."},{"key":"10.1016\/j.nsa.2022.100111_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychires.2022.01.044","article-title":"Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort \u2013 a five-year mirror image study","author":"Wallman","year":"2022","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.nsa.2022.100111_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jad.2016.03.043","article-title":"Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder","volume":"197","author":"Wu","year":"2016","journal-title":"J.\u00a0Affect. Disord."},{"issue":"1","key":"10.1016\/j.nsa.2022.100111_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/08039488.2021.1931714","article-title":"Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder - a naturalistic mirror image study","volume":"76","author":"Y\u0131ld\u0131zhan","year":"2022","journal-title":"Nord. J. Psychiatr."}],"container-title":["Neuroscience Applied"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408522001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408522001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T02:24:17Z","timestamp":1730946257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772408522001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":57,"alternative-id":["S2772408522001119"],"URL":"https:\/\/doi.org\/10.1016\/j.nsa.2022.100111","relation":{},"ISSN":["2772-4085"],"issn-type":[{"value":"2772-4085","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of long-acting injectable antipsychotics in a large naturalistic cohort across two European centers: Findings from the long-acting injectable antipsychotics collaborative (LAICO) study.","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Applied","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nsa.2022.100111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology.","name":"copyright","label":"Copyright"}],"article-number":"100111"}}